- Home
- AVNS vs LXRX Comparison
AVNS vs LXRX Comparison
Compare AVNS & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVNS | LXRX |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.7M | 547.4M |
| IPO Year | 2014 | 2000 |
Fundamental Metrics
Financial Performance| Metric | AVNS | LXRX |
|---|---|---|
| Price | $13.15 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.15 |
| AVG Volume (30 Days) | 551.7K | ★ 2.3M |
| Earning Date | 05-25-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.59 | 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $701,200,000.00 | $49,803,000.00 |
| Revenue This Year | $3.28 | N/A |
| Revenue Next Year | $4.23 | $22.16 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.95 | ★ 60.24 |
| 52 Week Low | $9.30 | $0.32 |
| 52 Week High | $15.68 | $1.83 |
Technical Indicators
Market Signals| Indicator | AVNS | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 62.43 |
| Support Level | $10.94 | $1.08 |
| Resistance Level | $15.68 | $1.83 |
| Average True Range (ATR) | 0.58 | 0.12 |
| MACD | -0.21 | 0.01 |
| Stochastic Oscillator | 17.13 | 72.60 |
Price Performance
Historical ComparisonAbout AVNS Avanos Medical Inc.
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.